Advocacy intelligence hub — real-time data for patient organizations
Indiana University — EARLY_PHASE1
Guangzhou FineImmune Biotechnology Co., LTD. — PHASE1
Centre Hospitalier Universitaire Vaudois — PHASE1
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — PHASE2
University Health Network, Toronto — PHASE2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — NA
Immunolight, LLC — PHASE1
Presage Biosciences — EARLY_PHASE1
Sheffield Teaching Hospitals NHS Foundation Trust
M.D. Anderson Cancer Center — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Vincent Chung, MD
City of Hope Medical Center
📍 DUARTE, CA
James L Gulley, M.D., MD PhD FACP
National Cancer Institute (NCI)
📍 BETHESDA, MD
Dawn Pinchasik, MD, M.D
TScan Therapeutics, Inc.
📍 PITTSBURGH, PA
Michal Lotem, MD
Hadassah Medical Organization
Ernest C. Borden, MD
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Timothy A Yap, MD, MD
M.D. Anderson Cancer Center
📍 HOUSTON, TX